The company conducts operations relating to business document solutions, medical imaging and diagnostics equipment, cosmetics, regenerative medicine, stem cells, biologics manufacturing, optical films for flat panel displays, optical devices, photocopiers and printers, digital cameras, color film, color paper, photofinishing equipment, photofinishing chemicals, graphic arts equipment and materials.
Fuji Photo Film Co., Ltd. was established in 1934 as a subsidiary of Daicel with the aim of producing photographic films. Over the following 10 years, the company produced photographic films, motion-picture films and X-ray films. In the 1940s, Fuji Photo entered the optical glasses, lenses and equipment markets. After the Second World War, Fuji Photo diversified, penetrating the medical (X-ray diagnosis), printing, electronic imaging and magnetic materials fields. In 1962, Fuji Photo and UK-based Rank Xerox Limited (now Xerox Limited) launched Fuji Xerox Co., Ltd. through a joint venture.
From the mid-1950s, Fuji Photo accelerated the establishment of overseas sales bases. In the 1980s, Fuji Photo expanded its production and other bases overseas, stepping up the pace of its business globalization. Meanwhile, Fuji Photo developed digital technologies for its photo-related, medical and printing businesses. As a result, it invented computed radiography (CR), which solved a number of issues of traditional radiography, resulting a decrease of radiation exposure to both technician and patient.
The new millennium witnessed the rapid spread of digital technology, and demand for photographic films plunged in line with the growing popularity of digital cameras. In response, Fuji Photo implemented management reforms aimed at drastic transformation of its business structures. Even as early as the 1980s, the company had foreseen the switch from film to digital, so "it developed a three-pronged strategy: to squeeze as much money out of the film business as possible, to prepare for the switch to digital and to develop new business lines."
On September 19, 2006, Fujifilm announced plans to establish a holding company, Fujifilm Holdings Corp. Fujifilm and Fuji Xerox would become subsidiaries of the holding company.
In late 2019, Fujifilm announced its acquisition of Xerox's 25% stake in the 57-year-old joint venture, Fuji Xerox.
In December 2019, Fujifilm acquired Hitachi's diagnostic imaging business for US$1.63 billion.
Amid the 2020 COVID-19 pandemic, one of Fujifilm Toyama Chemical drugs, i.e. favipiravir, an antiviral commercially named Avigan, is being considered as a possible cure to the virus, after having been approved by China, Russia, and Indonesia authorities by June 2020.
In June 2020, Fujifilm announced a US$928 million investment to a Denmark-based biologics production facility, which it acquired from Biogen a year earlier for around US$890 million, to double the manufacturing capacity.
According to en.wikipedia.org